Is prescription decrease of Twynsta, a leading hypertension treatment, temporary?

Sales of ‘Twynsta(Boehringer Ingelheim, Yuhan Corporation),’ a hypertension treatment which became a KRW 80 billion leading product based on its product and sales power in the fever of complex drugs, have drawn a downward curve.

The phenomenon was analyzed have the influence of causes, such as a number of complex generic launches for the same ARB+CCB-type like Exforge and Sevikar and the drug ...